Form 4 for DMAC DiaMedica Therapeutics Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001872863-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | 2026-01-02 | DMAC | Semba Charles Pauling | Dir | A - Grant | $8.42 | +3,355 | 48.0K | +8% | +$28.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 3,355 | $8.42 | 47,963 | D | — | — | (F1) Shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026." |